Pharmacological profile of dexketoprofen in orofacial pain
Author
dc.contributor.author
Miranda Guzmán, Hugo
Author
dc.contributor.author
Sierralta García, Fernando
Author
dc.contributor.author
Aranda Ortega, Nicolás
Author
dc.contributor.author
Noriega Sepúlveda, Viviana
Author
dc.contributor.author
Prieto Domíngez, Juan Carlos
Admission date
dc.date.accessioned
2017-11-29T18:02:43Z
Available date
dc.date.available
2017-11-29T18:02:43Z
Publication date
dc.date.issued
2016
Cita de ítem
dc.identifier.citation
Pharmacological Reports 68 (2016) 1111–1114
es_ES
Identifier
dc.identifier.issn
1734-1140
Identifier
dc.identifier.other
10.1016/j.pharep.2016.06.015
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/145911
Abstract
dc.description.abstract
Background: Non-steroidal anti-inflammatory drugs (NSAIDs) may act through others mechanisms, in addition to inhibition of prostaglandin synthesis. These includes cholinergic, NO, serotonergic and opioids pathways.
Methods: The aim of this work was to evaluate the effect of systemic action of (S)-+-ketoprofen (dexketoprofen, DEX) on pain behaviors using the orofacial formalin test in mice and the potential involvement of cholinergic, NO, serotonergic and opioids pathways.
Results: The pretreatment of the mice with 1 mg/kg ip of atropine or opoid antagonists: 1 mg/kg, ip of NTX or 1 mg/kg ip of NTI or 1 mg/kg of NOR-BNI ip, did not produce significant change in the ED50 values of the antinociception to orofacial test induced by DEX. The pretreatment of the mice with 0.5 mg/kg ip tropisetron, increased in a significant fashion the values of ED50 of DEX. When the mice were treated with 5 mg/kg ip of L-NAME or 25 mg/kg ip of aminoguanidine or 50 mg/kg ip of 7-nitroindazole reversed the antinociception of DEX.
Conclusion: The findings of this study demonstrate activation of NO and 5-HTpathways play important roles in the systemic antinociceptive effect of DEX in a murine model of inflammatory pain